Safety, Tolerability, and Pharmacokinetics of Single and Multiple Dose JPI-289, A Novel Poly (ADP-Ri...
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Dose JPI-289, A Novel Poly (ADP-Ribose) Polymerase-1 Inhibitor in First-In-Human Study of Healthy Volunteers
About this item
Full title
Author / Creator
Publisher
Bridgewater: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
Bridgewater: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
Background JPI-289 is a promising poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor with therapeutic potential for acute ischemic stroke by suppressing microglial activation and facilitating neuroprotection. The plasma and urine concentrations of JPI-289 and its metabolites were determined using a validated liquid chromatography-mass spectrometry m...
Alternative Titles
Full title
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Dose JPI-289, A Novel Poly (ADP-Ribose) Polymerase-1 Inhibitor in First-In-Human Study of Healthy Volunteers
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1912663373
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1912663373
Other Identifiers
ISSN
0149-2918
E-ISSN
1879-114X
DOI
10.1016/j.clinthera.2017.05.148
